Temporal dynamics and drivers of durable HIV viral load suppression and persistent high- and low-level viremia during Universal Test and Treat scale-up in Uganda: a population-based study
Rosen, J. G.; Ssekubugu, R. G.; Chang, L. W.; Ssempijja, V.; Galiwango, R. M.; Ssekasanvu, J.; Ndyanabo, A.; Kisakye, A.; Nakigozi, G.; Rucinski, K.; Patel, E.; Kennedy, C. E.; Nalugoda, F.; Kigozi, G.; Ratmann, O.; Nelson, L. J.; Mills, L. A.; Kabatesi, D.; Tobian, A. A.; Quinn, T. C.; Kagaayi, J.; Reynolds, S. J.; Grabowski, M. K.
Show abstract
IntroductionPopulation-level data on durable HIV viral load suppression (VLS) following implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viremia among persons living with HIV in 40 Ugandan communities during UTT scale-up. MethodsIn 2015-2020, we measured VLS (defined as <200 RNA copies/mL) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/mL) or high-level ([≥]1,000 copies/mL) viremia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e., visit-pairs; [~]18 month visit intervals) and classified as durable VLS (<200 copies/mL at both visits), new/renewed VLS (<200 copies/mL at follow-up only), viral rebound (<200 copies/mL at initial visit only), or persistent viremia (<200 copies/mL at neither visit). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viremia were also assessed using multivariable Poisson regression with generalized estimating equations. ResultsOverall, 3,080 participants contributed 4,604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with viremia at the initial visit (n=1,083), 46.9% maintained viremia through follow-up, 91.3% of which was high-level viremia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viremia self-reported antiretroviral therapy (ART) use for [≥]12 months. Prevalence of persistent high-level viremia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (versus 40-49-year-olds; adjusted risk ratio [adjRR]=2.96; 95% confidence interval [95%CI]:2.21-3.96), men (versus women; adjRR=2.40, 95%CI:1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (versus persons with marital/permanent partners only; adjRR=1.38, 95%CI:1.10-1.74), and persons exhibiting hazardous alcohol use (adjRR=1.09, 95%CI:1.03-1.16). The prevalence of persistent high-level viremia was highest among men <30 years (32.0%). ConclusionsFollowing universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting viremia, nearly half maintain high-level viremia for [≥]12 months and report higher-risk behaviors associated with onward HIV transmission. Enhanced linkage to HIV care and optimized treatment retention could accelerate momentum towards HIV epidemic control.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Trends in HIV self-testing uptake in Africa: a modeling study of population-based surveys and HIV testing program data 93%
- Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta regression analyzing influencing factors 90%
- Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: an individual patient data meta-analysis 90%
Similar papers in this journal
- Point-of-care HIV viral load testing in a community antiretroviral therapy delivery programme: a randomised controlled trial (PHILA) 92%
- Adherence Monitoring Methods to Measure Virological Failure in People Living with HIV on Long-Term Antiretroviral Therapy in Uganda 92%
- Economic evaluation of a cluster randomized, non-inferiority trial of differentiated service delivery models of HIV treatment in Zimbabwe 91%
Similar papers in this journal
- Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study 95%
- Household transmission of SARS-CoV-2 from adult index cases living with and without HIV in South Africa, 2020-2021: a case-ascertained, prospective observational household transmission study 94%
- Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk 93%
Similar papers in this journal
- Rapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease 96%
- Anti-spike antibody response to natural SARS-CoV-2 infection in the general population 93%
- High residual prevalence of vaccine-serotype Streptococcus pneumoniae carriage after introduction of a pneumococcal conjugate vaccine in Malawi: a prospective serial cross-sectional study 93%
Similar papers in this journal
- Sexual exposures associated with mpox infection: California, November 2022 to June 2023 93%
- Projected HIV and Bacterial STI Incidence Following COVID-Related Sexual Distancing and Clinical Service Interruption 91%
- SARS-CoV-2 virus dynamics in recently infected people – data from a household transmission study 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.